Status:
UNKNOWN
A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIR Study)
Lead Sponsor:
Tongji Hospital
Conditions:
End Stage Liver Disease
Infection
Eligibility:
All Genders
Brief Summary
The term of End Stage of Liver Disease (ESLD) was raised in 80's of 20 Century, but without a restrict definition. Infections are the cause and effect in occurrence and development of ESLD, which not ...
Eligibility Criteria
Inclusion
- Decompensation of liver cirrhosis:
- ALB \<35 g / L; A / G \<1.0
- TBIL\> 35μmol / L;
- ALT\> 1 × ULN and / or AST\> 1 × ULN
- PTA \<60%
- Ascites or hepatic encephalopathy or esophageal variceal bleeding
- Acute-on-chronic liver failure:
- Chronic liver disease based on: chronic hepatitis or decompensated cirrhosis
- onset time: \<4 weeks
- Hepatic encephalopathy: with or without
- Coagulation: PTA ≤ 40% or INR ≥ 1.5
- Jaundice: TBIL ≥ 171μmol / L or daily increase ≥ 17.1μmol / L
- Chronic liver failure:
- The basis of chronic liver disease: decompensated cirrhosis
- onset time: -
- Hepatic encephalopathy: with or without
- Coagulation: PTA ≤ 40% or INR ≥ 1.5 Jaundice: significantly higher
Exclusion
- \-
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03363451
Start Date
February 1 2018
End Date
December 31 2018
Last Update
September 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030